Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors
Oya, M.Armstrong, A. J.
Thiery-Vuillemin, A.
Shore, N.
Procopio, G.
Arslan, C.
Mehra, N.
Parnis, F.
Brown, E.
Schlurmann, F. C.
Joung, J. Y.
Sugimoto, M.
Sartor, O.
Liu, Y. Z.
Poehlein, C. H.
Desai, C.
Del Rosario, P. M. D.
Clarke, Noel W
Saad, F.
Affiliation
Department of Urology, Keio University School of Medicine, Shinjuku-ku, JapanIssue Date
2022
Metadata
Show full item recordCitation
Oya M, Armstrong AJ, Thiery-Vuillemin A, Shore N, Procopio G, Arslan C, et al. Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 2022 Nov;38(9):S1495-S. PubMed PMID: WOS:000897943700159.Journal
Annals of OncologyDOI
10.1016/j.annonc.2022.10.194Additional Links
https://dx.doi.org/10.1016/j.annonc.2022.10.194Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.annonc.2022.10.194